ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QL2401

A development code. Also written as “QL2401 25 mg”, “QL2401 50 mg” and “QL2401 100 mg”.

Its studies are mostly in Fatty Liver, led by Qilu Pharmaceutical.

Furthest: phase 2, since May 27, 20262 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical21 open or runningphase 2since May 27, 2026Dec 29, 2025Jun 2027phase 2 · NCT07620366

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 29, 2025First study: phase 1 study in Metabolic Dysfunction-Associated Steatohepatitis(MASH)First studyNCT07331545 · 71 enrolled · China
  2. May 27, 2026Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)Phase 2 reachedNCT07620366 · 132 planned

Ahead

  1. Jun 2027Primary completion: phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT07620366

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07620366Metabolic Dysfunction-associated Steatohepatitis (MASH)2Not yet recruitingJun 2027132
NCT07331545Metabolic Dysfunction-Associated Steatohepatitis(MASH) · China1CompletedJun 24, 202671

How it is read

Names in the registry

  • “QL2401 25 mg”, 1 entry
  • “QL2401 50 mg”, 1 entry
  • “QL2401 100 mg”, 1 entry
  • “QL2401”, 1 entry

Codes read as this program: QL2401.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.